Home

Todd Newton

CIK 1460878 · Interim CEO · last filed 2026-06-12

Todd Newton is an Interim CEO who has filed 25 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing shows the insider was granted $185.3K of MDXG on Jun 12, 2026. Across all open-market trades the lifetime net is +$1.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.59M

Companies

4

Total Filings

25

Lifetime Open-Market Net

$1.46M

Filer Profile

Reported Address
1120 S CAPITAL OF TX HWY
BUILDING ONE, STE 300
AUSTIN, TX 78746
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MDXG Interim CEO 463,684 $4.57 $2.12M $0 9 2026-06-12
Apollo Endosurgery, Inc. (APEN) Delisted Chief Executive Officer 412,306 $10.00 $4.12M $1.25M 10 2021-01-07
Apollo Endosurgery, Inc. (LPTN) Delisted Chief Executive Officer 5,208 — — $0 1 2016-12-29
ARTC SVP, CFO & COO 47,214 $10.00 $472.1K $203.6K 5 2013-06-21

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 MDXG Grant (A) +50,913 $185.3K EDGAR
2025-06-23 MDXG Grant (A) +28,609 $185.1K EDGAR
2024-06-06 MDXG Grant (A) +23,190 $168.4K EDGAR
2023-06-15 MDXG Grant (A) +35,354 $175.0K EDGAR
2022-09-19 MDXG Grant (A) +200,000 $0 EDGAR
2022-06-13 MDXG Grant (A) +44,191 $175.0K EDGAR
2021-05-28 MDXG Grant (A) +17,056 $175.0K EDGAR
2021-01-07 Apollo Endosurgery, Inc. (APEN) Delisted Other (J) +3,479 $0 EDGAR
2020-10-05 MDXG Grant (A) +26,236 $175.0K EDGAR
2020-08-06 MDXG Grant (A) +38,135 $0 EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.